查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1609560

基于体学的临床试验市场规模、份额和趋势分析报告：2025-2030 年按阶段、研究设计、适应症、地区和细分市场进行的预测

Omics-based Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional Studies, Observational Studies), By Indication, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

基于体学的临床试验市场成长与趋势

Grand View Research, Inc. 的最新报告显示，到 2030 年，全球基于体学的临床试验市场规模预计将达到 517.7 亿美元。

预计2025年至2030年该市场将以8.02%的复合年增长率扩张。体学已被证明是分子研究的前沿方法。体学包括生物科学的所有领域。不同的部分被归类为体学，包括蛋白质组学、基因组学、转录组学和代谢体学。冠状病毒的爆发加速了临床试验中新方法、模型和技术的采用，这对市场成长产生了积极影响。

COVID-19 的爆发造成了严重破坏，几乎扰乱了每个行业。最初，COVID-19 的爆发对临床试验生态系统产生了负面影响，影响了许多正在进行的针对多种适应症的试验。然而，在 2020 年底，研究人员开始开发 COVID-19 的创新疗法和疫苗，支持市场復苏和成长以及 CRO业务永续营运。癌症领域的临床试验活动不断增加，癌症领域的临床试验达到历史最高水准。了解 COVID-19 感染的广泛研究将注意力集中在基于体学研究的应用上。

例如，2021 年 6 月，图宾根大学医院的一组研究人员启动了一项临床试验，利用多组体学方法对不同候选 COVID-19 疫苗的遗传和免疫反应进行比较分析。空间体学在生物标记识别中的日益增长的应用是推动市场成长的关键因素。为了研究药物功效和毒性，空间组体学发挥重要作用，简化了药物发现和开发。生物标记鑑定广泛应用于药物开发和药物发现以及临床应用。生物标记用于识别疾病途径、进展并阐明原因。

心臟疾病等慢性病盛行率不断上升，以及新兴市场对基于体学的临床试验的需求不断增长，正在推动市场成长。癌症是美国的主要原因之一。光是 2018 年，估计就有 1,735,350 例新诊断和 609,640 例癌症相关死亡。单细胞多组学分析是一种新工具，为癌症治疗开发打开了大门，并推进了当前的治疗选择。该市场也受到生技药品的成长、对先进技术的需求以及对个人化药物和孤儿药的需求的推动。此外，生物技术和製药行业的成长正在推动对非侵入性设备、单细胞多组体学技术的完整应用以及传统实验室的需求，从而推动未来市场的成长。

基于体学的临床试验市场报告亮点

  • III期细分市场占据主导地位，2024年占总收益占有率的54.5%。根据临床试验统计数据，市场成长是由三期试验的增加所推动的，三期试验通常涉及更多的市场参与企业。
  • 2024 年，由于人们越来越重视个人化医疗，透过体学技术对个别病患资料进行客製化干预，干预研究领域占据了市场主导地位。
  • 由于全球癌症发病率不断上升以及对更有效治疗策略的需求不断增长，癌症细分市场将在 2024 年占据市场主导地位。
  • 北美组体学临床试验市场在全球产业中占据主导地位，2024年市占率将达到38.0%。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章以体学为基础的临床试验市场变数、趋势、范围

  • 市场体系展望
    • 母市场展望
    • 相关/补充市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 市场分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19 影响分析

第四章基于体学的临床试验市场：阶段、估计和趋势分析

  • 细分仪表板
  • 全球体学临床试验市场，相变分析
  • 2018-2030 年基于体学的临床试验规模和趋势（按阶段）的全球分析
  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 第四阶段

第五章 以体学的临床试验市场：研究设计、估计与趋势分析

  • 细分仪表板
  • 全球组体学临床试验市场、试验设计变异分析
  • 2018-2030 年按研究设计分類的基于体学的临床试验规模和趋势的全球分析
  • 干预研究
  • 观察性研究
  • 扩大访问研究

第六章以体学的临床试验市场：适应症、估计与趋势分析

  • 细分仪表板
  • 全球组体学临床试验市场、适应症变异分析
  • 2018-2030 年基于体学的临床试验规模和适应症趋势的全球分析
  • 自体免疫/炎症
  • 疼痛管理
  • 癌症
  • 中枢神经系统状况
  • 糖尿病
  • 肥胖
  • 心血管
  • 其他的

第七章基于体学的临床试验市场：区域、估计和趋势分析

  • 2024 年及 2030 年按地区分類的市场占有率分析
  • 区域市场仪表板
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 公司分类
  • 2024 年企业市场分析
  • 公司简介
    • Parexel International（MA）Corporation
    • Thermo Fisher Scientific Inc.
    • Charles River Laboratories
    • ICON plc
    • SGS Societe Generale de Surveillance SA
    • Eli Lilly and Company
    • Pfizer Inc.
    • Laboratory Corporation of America
    • Novo Nordisk A/S
    • Rebus Biosystems, Inc.
Product Code: GVR-4-68039-905-9

Omics-Based Clinical Trials Market Growth & Trends:

The global omics-based clinical trials market size is anticipated to reach USD 51.77 billion by 2030, according to the new report of Grand View Research, Inc. The market is expected to expand at a CAGR of 8.02% from 2025 to 2030. Omics has turned out to be the most advanced approach in molecular research. It includes all the field of biological sciences that ends with the suffix - omics. Various disciplines can be classified as omics such as proteomics, genomics, transcriptomics, and metabolomics. The outbreak of coronavirus accelerated the adoption of new approaches, models, and technology in clinical trials, this has positively impacted market growth.

The outbreak of COVID-19 has caused havoc and has disrupted almost every sector of industry. Initially, the outbreak has negatively impacted the ecosystem of clinical trials and affected many ongoing studies for numerous indications. However, in the second half of 2020, researchers started developing innovative therapeutics and vaccines against COVID-19, which has supported the market recovery and growth, and continuance of business by CROs. There has been an increase in the clinical trials activity with oncology trials attaining historically high levels. The extensive research for understanding the COVID-19 infection has turned the attention to the application of omics-based studies.

For instance, in June 2021, a group of researchers at University Hospital Tuebingen initiated a clinical trial on comparative genetic and immune response analysis of different COVID-19 vaccine candidates using a multi-omics approach. The growing application of spatial OMICS, for the identification of biomarkers, is a major factor boosting the growth of the market. To study the efficacy and toxicity of the drug, spatial OMICS play a major role and have simplified drug discovery and development. Biomarker identification along with the clinical application is widely used in drug development and discovery. Biomarkers are used to identify the pathway of the diseases and the progression and help to understand the cause.

The rising prevalence of chronic diseases such as cancer and cardiac disorders and the increasing demand for omics-based clinical trials in developing countries are boosting the market's growth. Cancer is one of the leading causes of death in the United States. In 2018 alone, there were an estimated 1,735,350 new diagnoses and 609,640 cancer-related deaths. Single-cell multi-OMIC analysis is a novel tool that is opening doors in cancer drug development and further advance the current treatment options. The market is also driven by a rising number of biologics, demand for advanced technologies, and the need for personalized medicines and orphan drugs. Additionally, growing biotechnology and the pharmaceutical industry have propelled the demand for non-invasive instruments, full applications for single-cell multi-omics technology, and conventional labs are bolstering future market growth.

Omics-Based Clinical Trials Market Report Highlights:

  • The phase III segment dominated the market, accounting for 54.5% of the total revenue share in 2024. Clinical trial statistics indicate that market growth is driven by an increase in phase III trials, which typically involve a large number of participants.
  • The interventional studies segment dominated the market in 2024 owing to its growing emphasis on personalized medicine by facilitating tailored interventions based on individual patient profiles derived from omics technologies.
  • The oncology segment dominated the market in 2024 owing to increasing prevalence of cancer globally coupled with growing need for more effective treatment strategies.
  • North America omics-based clinical trials market dominated the global industry and accounted for a 38.0% share in 2024.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity Flow Analysis
    • 1.6.2. Bottom-up Approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Abbreviations
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Omics-Based Clinical Trials Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising Investment by Major Pharmaceutical Companies
      • 3.2.1.2. Shift Towards Personalized Medicine
      • 3.2.1.3. Growing Prevalence of Chronic Disorders
      • 3.2.1.4. Increasing Partnership and Collaboration
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Rising Costs of Clinical Trials
  • 3.3. Market Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Omics-Based Clinical Trials Market: Phase Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Omics-Based Clinical Trials Market; Phase Movement Analysis
  • 4.3. Global Omics-Based Clinical Trials Size & Trend Analysis, by Phase, 2018 to 2030 (USD Million)
  • 4.4. Phase I
    • 4.4.1. Phase I market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Phase II
    • 4.5.1. Phase II market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Phase III
    • 4.6.1. Phase III market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Phase IV
    • 4.7.1. Phase IV market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Omics-Based Clinical Trials Market: Study Design Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Omics-Based Clinical Trials Market; Study Design Movement Analysis
  • 5.3. Global Omics-Based Clinical Trials Size & Trend Analysis, by Study Design, 2018 to 2030 (USD Million)
  • 5.4. Interventional Studies
    • 5.4.1. Interventional studies market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Observational Studies
    • 5.5.1. Observational studies market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Expanded Access Studies
    • 5.6.1. Expanded access studies market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Omics-Based Clinical Trials Market: Indication Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Omics-Based Clinical Trials Market; Indication Movement Analysis
  • 6.3. Global Omics-Based Clinical Trials Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)
  • 6.4. Autoimmune/inflammation
    • 6.4.1. Autoimmune/inflammation market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Pain management
    • 6.5.1. Pain management market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Oncology
    • 6.6.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. CNS conditions
    • 6.7.1. CNS conditions market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Diabetes
    • 6.8.1. Diabetes market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. Obesity
    • 6.9.1. Obesity market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.10. Cardiovascular
    • 6.10.1. Cardiovascular market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.11. Others
    • 6.11.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Omics-Based Clinical Trials Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. North America
    • 7.3.1. North America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Competitive scenario
      • 7.3.2.3. Regulatory framework
      • 7.3.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Competitive scenario
      • 7.3.3.3. Regulatory framework
      • 7.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.4. Mexico
      • 7.3.4.1. Key country dynamics
      • 7.3.4.2. Competitive scenario
      • 7.3.4.3. Regulatory framework
      • 7.3.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Competitive scenario
      • 7.4.2.3. Regulatory framework
      • 7.4.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Competitive scenario
      • 7.4.3.3. Regulatory framework
      • 7.4.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. France
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Competitive scenario
      • 7.4.4.3. Regulatory framework
      • 7.4.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Italy
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Competitive scenario
      • 7.4.5.3. Regulatory framework
      • 7.4.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Spain
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Competitive scenario
      • 7.4.6.3. Regulatory framework
      • 7.4.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Denmark
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Competitive scenario
      • 7.4.7.3. Regulatory framework
      • 7.4.7.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Sweden
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Competitive scenario
      • 7.4.8.3. Regulatory framework
      • 7.4.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.9. Norway
      • 7.4.9.1. Key country dynamics
      • 7.4.9.2. Competitive scenario
      • 7.4.9.3. Regulatory framework
      • 7.4.9.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia Pacific Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Japan
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Competitive scenario
      • 7.5.2.3. Regulatory framework
      • 7.5.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. China
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Competitive scenario
      • 7.5.3.3. Regulatory framework
      • 7.5.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. India
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Competitive scenario
      • 7.5.4.3. Regulatory framework
      • 7.5.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. Australia
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Competitive scenario
      • 7.5.5.3. Regulatory framework
      • 7.5.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. South Korea
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Competitive scenario
      • 7.5.6.3. Regulatory framework
      • 7.5.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.7. Thailand
      • 7.5.7.1. Key country dynamics
      • 7.5.7.2. Competitive scenario
      • 7.5.7.3. Regulatory framework
      • 7.5.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Brazil
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Competitive scenario
      • 7.6.2.3. Regulatory framework
      • 7.6.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Competitive scenario
      • 7.6.3.3. Regulatory framework
      • 7.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. MEA Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Competitive scenario
      • 7.7.2.3. Regulatory framework
      • 7.7.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. Saudi Arabia
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Competitive scenario
      • 7.7.3.3. Regulatory framework
      • 7.7.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. UAE
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Competitive scenario
      • 7.7.4.3. Regulatory framework
      • 7.7.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. Kuwait
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Competitive scenario
      • 7.7.5.3. Regulatory framework
      • 7.7.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Company Market Position Analysis, 2024
  • 8.3. Company Profiles
    • 8.3.1. Parexel International (MA) Corporation
      • 8.3.1.1. Company overview
      • 8.3.1.2. Financial performance
      • 8.3.1.3. Service benchmarking
      • 8.3.1.4. Strategic initiatives
    • 8.3.2. Thermo Fisher Scientific Inc.
      • 8.3.2.1. Company overview
      • 8.3.2.2. Financial performance
      • 8.3.2.3. Service benchmarking
      • 8.3.2.4. Strategic initiatives
    • 8.3.3. Charles River Laboratories
      • 8.3.3.1. Company overview
      • 8.3.3.2. Financial performance
      • 8.3.3.3. Service benchmarking
      • 8.3.3.4. Strategic initiatives
    • 8.3.4. ICON plc
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Service benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. SGS Societe Generale de Surveillance SA
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Service benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Eli Lilly and Company
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Service benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Pfizer Inc.
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Service benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Laboratory Corporation of America
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Service benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Novo Nordisk A/S
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Service benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Rebus Biosystems, Inc.
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Service benchmarking
      • 8.3.10.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 4 Global Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 5 Global Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 6 Global Omics-Based Clinical Trials Market, by Region, 2018 - 2030 (USD Million)
  • Table 7 North America Omics-Based Clinical Trials Market, by Country, 2018 - 2030 (USD Million)
  • Table 8 North America Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 9 North America Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 10 Global Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 11 U.S. Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 12 U.S. Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 13 U.S. Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 14 Canada Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 15 Canada Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 16 Canada Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 17 Mexico Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 18 Mexico Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 19 Mexico Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 20 UK Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 21 UK Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 22 UK Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 23 Germany Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 24 Germany Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 25 Germany Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 26 France Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 27 France Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 28 France Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 29 Italy Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 30 Italy Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 31 Italy Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 32 Spain Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 33 Spain Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 34 Spain Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 35 Sweden Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 36 Sweden Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 37 Sweden Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 38 Norway Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 39 Norway Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 40 Norway Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 41 Denmark Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 42 Denmark Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 43 Denmark Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 44 India Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 45 India Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 46 India Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 47 China Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 48 China Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 49 China Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 50 Japan Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 51 Japan Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 52 Japan Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 53 India Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 54 India Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 55 India Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 56 Australia Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 57 Australia Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 58 Australia Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 59 Thailand Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 60 Thailand Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 61 Thailand Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 62 South Korea Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 63 South Korea Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 64 South Korea Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 65 Brazil Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 66 Brazil Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 67 Brazil Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 68 Argentina Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 69 Argentina Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 70 Argentina Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 71 Saudi Arabia Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 72 Saudi Arabia Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 73 Saudi Arabia Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 74 UAE Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 75 UAE Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 76 UAE Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 77 Kuwait Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 78 Kuwait Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 79 Kuwait Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Omics-Based Clinical Trials Market, Market Segmentation
  • Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 9 Porter's Five Forces Analysis
  • Fig. 10 PESTEL Analysis
  • Fig. 11 Regional Marketplace: Key Takeaways
  • Fig. 12 Global Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 13 Global Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 14 Global Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 15 Global Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 16 Global Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 17 Global Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 18 Global Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 19 Global Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 20 Global Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 21 Global Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 22 Global Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 23 Global Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 24 Global Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 25 Global Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 26 Global Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
  • Fig. 27 North America Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 28 North America Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 29 North America Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 30 North America Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 31 North America Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 32 North America Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 33 North America Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 34 North America Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 35 North America Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 36 North America Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 37 North America Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 38 North America Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 39 North America Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 40 North America Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 41 North America Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
  • Fig. 42 U.S. Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 43 U.S. Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 44 U.S. Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 45 U.S. Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 46 U.S. Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 47 U.S. Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 48 U.S. Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 49 U.S. Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 50 U.S. Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 51 U.S. Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 52 U.S. Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 53 U.S. Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 54 U.S. Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 55 U.S. Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 56 U.S. Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
  • Fig. 57 Canada Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 58 Canada Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 59 Canada Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 60 Canada Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 61 Canada Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 62 Canada Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 63 Canada Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 64 Canada Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 65 Canada Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 66 Canada Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 67 Canada Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 68 Canada Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 69 Canada Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 70 Canada Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 71 Canada Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
  • Fig. 72 Mexico Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 73 Mexico Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 74 Mexico Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 75 Mexico Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 76 Mexico Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 77 Mexico Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 78 Mexico Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 79 Mexico Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 80 Mexico Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 81 Mexico Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 82 Mexico Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 83 Mexico Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 84 Mexico Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 85 Mexico Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 86 Mexico Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
  • Fig. 87 Europe Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 88 Europe Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 89 Europe Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 90 Europe Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 91 Europe Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 92 Europe Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 93 Europe Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 94 Europe Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 95 Europe Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 96 Europe Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 97 Europe Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 98 Europe Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 99 Europe Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 100 Europe Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 101 Europe Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
  • Fig. 102 UK Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 103 UK Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 104 UK Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 105 UK Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 106 UK Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 107 UK Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 108 UK Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 109 UK Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 110 UK Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 111 UK Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 112 UK Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 113 UK Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 114 UK Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 115 UK Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 116 UK Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
  • Fig. 117 UK Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 118 Germany Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 119 Germany Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 120 Germany Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 121 Germany Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 122 Germany Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 123 Germany Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 124 Germany Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 125 Germany Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 126 Germany Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 127 Germany Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 128 Germany Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 129 Germany Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 130 Germany Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 131 Germany Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
  • Fig. 132 France Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 133 France Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 134 France Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 135 France Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 136 France Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 137 France Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 138 France Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 139 France Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 140 France Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 141 France Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 142 France Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 143 France Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 144 France Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 145 France Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 146 France Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
  • Fig. 147 Italy Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 148 Italy Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 149 Italy Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 150 Italy Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 151 Italy Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 152 Italy Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 153 Italy Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 154 Italy Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 155 Italy Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 156 Italy Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 157 Italy Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 158 Italy Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 159 Italy Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 160 Italy Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 161 Italy Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
  • Fig. 162 Spain Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 163 Spain Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 164 Spain Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 165 Spain Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 166 Spain Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 167 Spain Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 168 Spain Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 169 Spain Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 170 Spain Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 171 Spain Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 172 Spain Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 173 Spain Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 174 Spain Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 175 Spain Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 176 Spain Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
  • Fig. 177 Denmark Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 178 Denmark Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 179 Denmark Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 180 Denmark Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 181 Denmark Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 182 Denmark Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 183 Denmark Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 184 Denmark Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 185 Denmark Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 186 Denmark Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 187 Denmark Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 188 Denmark Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 189 Denmark Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 190 Denmark Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 191 Denmark Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
  • Fig. 192 Sweden Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 193 Sweden Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 194 Sweden Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 195 Sweden Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 196 Sweden Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 197 Sweden Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 198 Sweden Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 199 Sweden Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 200 Sweden Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 201 Sweden Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 202 Sweden Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 203 Sweden Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 204 Sweden Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 205 Sweden Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 206 Sweden Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
  • Fig. 207 Norway Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 208 Norway Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 209 Norway Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 210 Norway Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 211 Norway Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 212 Norway Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 213 Norway Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 214 Norway Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 215 Norway Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 216 Norway Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 217 Norway Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 218 Norway Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 219 Norway Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 220 Norway Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 221 Norway Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
  • Fig. 222 Asia Pacific Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 223 Asia Pacific Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 224 Asia Pacific Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 225 Asia Pacific Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 226 Asia Pacific Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 227 Asia Pacific Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 228 Asia Pacific Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 229 Asia Pacific Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 230 Asia Pacific Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 231 Asia Pacific Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 232 Asia Pacific Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 233 Asia Pacific Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 234 Asia Pacific Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 235 Asia Pacific Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 236 Asia Pacific Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
  • Fig. 237 China Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 238 China Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 239 China Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 240 China Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 241 China Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 242 China Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 243 China Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 244 China Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 245 China Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 246 China Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 247 China Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 248 China Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 249 China Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 250 China Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 251 China Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
  • Fig. 252 Japan Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 253 Japan Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 254 Japan Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 255 Japan Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 256 Japan Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 257 Japan Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 258 Japan Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 259 Japan Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 260 Japan Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 261 Japan Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 262 Japan Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 263 Japan Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 264 Japan Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 265 Japan Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 266 Japan Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
  • Fig. 267 India Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 268 India Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 269 India Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 270 India Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 271 India Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 272 India Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 273 India Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 274 India Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 275 India Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 276 India Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 277 India Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 278 India Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 279 India Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 280 India Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 281 India Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
  • Fig. 282 Australia Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 283 Australia Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 284 Australia Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 285 Australia Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 286 Australia Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 287 Australia Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 288 Australia Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 289 Australia Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 290 Australia Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 291 Australia Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 292 Australia Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 293 Australia Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 294 Australia Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 295 Australia Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 296 Australia Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
  • Fig. 297 Thailand Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 298 Thailand Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 299 Thailand Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 300 Thailand Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 301 Thailand Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 302 Thailand Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 303 Thailand Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 304 Thailand Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 305 Thailand Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 306 Thailand Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 307 Thailand Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 308 Thailand Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 309 Thailand Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 310 Thailand Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 311 Thailand Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
  • Fig. 312 South Korea Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 313 South Korea Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 314 South Korea Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 315 South Korea Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 316 South Korea Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 317 South Korea Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 318 South Korea Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 319 South Korea Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 320 South Korea Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 321 South Korea Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 322 South Korea Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 323 South Korea Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 324 South Korea Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 325 South Korea Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 326 South Korea Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
  • Fig. 327 Latin America Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 328 Latin America Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 329 Latin America Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 330 Latin America Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 331 Latin America Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 332 Latin America Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 333 Latin America Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 334 Latin America Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 335 Latin America Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 336 Latin America Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 337 Latin America Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 338 Latin America Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 339 Latin America Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 340 Latin America Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 341 Latin America Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)